Novocure Ltd. (NVCR)

24.15
NASDAQ : Health Technology
Prev Close 24.15
Day Low/High 0.00 / 0.00
52 Wk Low/High 10.55 / 25.70
Avg Volume 901.10K
Exchange NASDAQ
Shares Outstanding 90.40M
Market Cap 2.21B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of NVCR May 18th Options Trading

First Week of NVCR May 18th Options Trading

Investors in NovoCure Ltd saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

NCCN Guidelines Recommend Optune In Combination With Temozolomide As A Category 1 Treatment For Newly Diagnosed Glioblastoma

NCCN Guidelines Recommend Optune In Combination With Temozolomide As A Category 1 Treatment For Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment...

Novocure Announces 35 Presentations On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2018

Novocure Announces 35 Presentations On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2018

Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14 through April 18, in Chicago.

Big Earnings Week Ahead: Cramer's 'Mad Money' Recap (Monday 2/26/18)

Big Earnings Week Ahead: Cramer's 'Mad Money' Recap (Monday 2/26/18)

Jim Cramer is keeping a close eye on retail earnings this week, along with testimony from new Fed Chair Jerome Powell.

Novocure Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Company Update

Novocure Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Novocure (NASDAQ: NVCR) announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in...

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival Without Negatively Influencing Health-Related Quality Of Life Compared To Temozolomide Alone In Newly Diagnosed GBM Patients

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival Without Negatively Influencing Health-Related Quality Of Life Compared To Temozolomide Alone In Newly Diagnosed GBM Patients

Novocure (NASDAQ: NVCR) announced today that a detailed quality of life analysis of Novocure's EF-14 phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM)...

First Week of September 21st Options Trading For NovoCure (NVCR)

First Week of September 21st Options Trading For NovoCure (NVCR)

Investors in NovoCure Ltd saw new options begin trading this week, for the September 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novocure Announces Fourth Quarter And Full Year 2017 Operating Statistics And Preliminary Revenue

Novocure Announces Fourth Quarter And Full Year 2017 Operating Statistics And Preliminary Revenue

Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited revenue for the fourth quarter and full year 2017.

Novocure To Participate In 36th Annual J.P. Morgan Healthcare Conference

Novocure To Participate In 36th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that it will participate in the 36th Annual J.

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced today that it has received a U.S.

Novocure Receives Reimbursement Approval For Optune® In Japan For The Treatment Of Newly Diagnosed Glioblastoma

Novocure Receives Reimbursement Approval For Optune® In Japan For The Treatment Of Newly Diagnosed Glioblastoma

Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan's Central Social Insurance Medical Council (Chuikyo) to provide reimbursement for...

Novocure To Present At Two Upcoming Investor Conferences In December

Novocure To Present At Two Upcoming Investor Conferences In December

Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December.

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.

Patients Who Used Optune® More Than 90 Percent Of The Time Had The Greatest Chance Of Survival In Novocure's EF-14 Trial: A Median Survival Of 24.9 Months From Randomization And A Five-Year Survival Of 29.3 Percent

Patients Who Used Optune® More Than 90 Percent Of The Time Had The Greatest Chance Of Survival In Novocure's EF-14 Trial: A Median Survival Of 24.9 Months From Randomization And A Five-Year Survival Of 29.3 Percent

Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance with Optune predicted increased survival in glioblastoma (GBM)...

Novocure Announces 28 Presentations On Tumor Treating Fields From Externally Led Clinical Research And Analysis At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces 28 Presentations On Tumor Treating Fields From Externally Led Clinical Research And Analysis At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ:NVCR) announced today 28 presentations on Tumor Treating Fields from externally led clinical research and analysis at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through...

Novocure Announces 13 Preclinical Presentations Highlighting Data On Tumor Treating Fields' Mechanism Of Action At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces 13 Preclinical Presentations Highlighting Data On Tumor Treating Fields' Mechanism Of Action At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ:NVCR) announced today 13 preclinical presentations highlighting data on Tumor Treating Fields' mechanism of action at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through...

Novocure Announces Six Clinical Presentations On Novocure's Phase 3 Pivotal EF-14 Trial Data In Newly Diagnosed Glioblastoma At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces Six Clinical Presentations On Novocure's Phase 3 Pivotal EF-14 Trial Data In Newly Diagnosed Glioblastoma At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ: NVCR) announced today six clinical presentations on Novocure's phase 3 pivotal EF-14 trial data in newly diagnosed glioblastoma (GBM) at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO),...

Novocure Reports Third Quarter 2017 Financial Results And Provides Company Update

Novocure Reports Third Quarter 2017 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.

Novocure Announces Data Presentations At The IASLC 18th World Conference On Lung Cancer

Novocure Announces Data Presentations At The IASLC 18th World Conference On Lung Cancer

Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18 th World Conference on Lung Cancer, October 15 to October 18 in Yokohama, Japan.

First Week of November 17th Options Trading For NovoCure (NVCR)

First Week of November 17th Options Trading For NovoCure (NVCR)

Investors in NovoCure Ltd saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

NovoCure Stock Sees Short Interest Drop 15.6%

NovoCure Stock Sees Short Interest Drop 15.6%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,030,438 share decrease in total short interest for NovoCure Ltd , to 5,566,567, a decrease of 15.62% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Novocure To Report Third Quarter 2017 Financial Results

Novocure To Report Third Quarter 2017 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2017 on Thursday, October 26, 2017, before the U.

Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers

Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers

The St. Helier, Jersey-based firm said a Phase 3 study of Optune in tandem with temozolomide in newly diagnosed glioblastoma "demonstrated unprecedented five-year survival results."

Combination Of Optune® With Temozolomide Demonstrates Unprecedented Five-Year Survival For Newly Diagnosed Glioblastoma Patients

Combination Of Optune® With Temozolomide Demonstrates Unprecedented Five-Year Survival For Newly Diagnosed Glioblastoma Patients

Novocure (NASDAQ: NVCR) announced today results from its phase 3 pivotal EF-14 trial adding Optune to temozolomide for the treatment of newly diagnosed glioblastoma (GBM), including results from health-related quality of...

Novocure Announces Data Presentations At The American Society For Radiation Oncology's 2017 Annual Meeting

Novocure Announces Data Presentations At The American Society For Radiation Oncology's 2017 Annual Meeting

Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TTFields) at the American Society for Radiation Oncology's (ASTRO) 2017 Annual Meeting, September 24 through September 27 in San Diego.

Monday Gains Bring a Warning

Gold falls during recovery rally.

Novocure Announces Data Presentations At The ESMO 2017 Congress

Novocure Announces Data Presentations At The ESMO 2017 Congress

Novocure (NASDAQ: NVCR) announced today that four data presentations on Tumor Treating Fields (TTFields) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 through September 12...

TheStreet Quant Rating: D+ (Sell)